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Introduction 
Arterial hypotension occurs frequently during anaesthesia with an incidence that varies 
between 5 to 99%1, this requires treatment in two third of cases. Some anaesthetic agents 
inhibit the release of catecholamine from sympathetic neurons while others create arterial and 
venous vasodilation, or have myocardial action. In cases of neuraxial anaesthetics (spinal or 
epidural), the extension of the sympathetic blockade generates hypotension by a reduction of 
cardiac preload. The achievement of hemodynamic stability is recommended during intra-
operatory period in order to reduce the risk of postoperative complications, particularly after 
major surgeries or among patients with comorbidities.2, 3  
Recent studies have demonstrated that intraoperative hypotension can induce severe adverse 
effects such as acute kidney injury or myocardial injury, this risk increasing with the duration 
of hypotension 3. In the delivery room, maternal blood pressure must be controlled during 
spinal anaesthesia in order to preserve foetal vitality. 4 
Among vasopressors available in French hospitals, phenylephrine, ephedrine and 
norepinephrine are the most commonly used. In 2011, two new forms of diluted 
phenylephrine were released (500g/10ml and 500g/5ml). In order to avoid medication 
errors by confusion, French heath regulatory authorities decided in 2013 to withdraw the 
marketing authorisation of concentrated phenylephrine (5mg/1ml).  
In this context, we measured the use of vasopressors in order to examine current trends in 
anaesthetic management of hypotension in the operative room.  
We hypothesised that diluted phenylephrine would become increasingly used while reducing 
the usage of other vasopressors. 
 
  
Materials et methods 
We conducted a longitudinal retrospective observational study between 2011 and 2014 in 
French university hospitals (Centres Hospitaliers Universitaires - CHU) and military 
hospitals (Hôpitaux d’Instruction des Armées - HIA) in order to collect consumption data for 
the three major sympathomimetic agents (phenylephrine, ephedrine and norepinephrine) 
within operative rooms. We included the 30 existing CHUs and nine existing HIAs (a total of 
39 hospitals). 
In February 2015, we emailed the hospital pharmacists of each centre a questionnaire. In the 
questionnaire, we listed the commercially available formulations of vasopressors in the 
French market: concentrated ampoule of ephedrine (30mg/1ml), diluted ampoule of ephedrine 
(30mg/10ml), prefilled syringe (PFS) of ephedrine (30mg/10ml), concentrated ampoule of 
phenylephrine (5mg/1ml), diluted ampoule of phenylephrine (500g/10ml and 500g/5ml), 
and ampoule of norepinephrine (8mg/4ml and 16mg/8ml).  
The pharmacist was asked to complete the questionnaire with the yearly number of ampoule 
and PFS delivered by hospital pharmacies to operating rooms (i.e. excluding drug dispensing 
to critical care units) over the period 2011-2014. Email reminders were sent to non-
responders. In the event of nonresponse, an email was sent to the Head of department of 
anaesthesia-critical care unit to obtain data.  
In cases where responders had stated that they were not able to identify drug delivery to 
operating rooms only, the centres were excluded from final analysis because clinical 
management for hemodynamic stability differs between operating rooms and critical care 
units.  
To facilitate data analysis, we categorised vasopressor forms into 5 groups: ephedrine 
ampoule of 30mg (diluted or concentrated); ephedrine PFS of 30mg; phenylephrine 
concentrated ampoule of 5mg; phenylephrine diluted ampoule of 500 g (5 or 10ml) and 
norepinephrine ampoule of 8 mg. In cases where responders stated the delivery of 
norepinephrine ampoules of 16mg, we converted the number into ampoules of 8mg (one 
ampoule of 16mg = 2 ampoules of 8mg). 
In order to address the possibility that the largest hospitals were likely to have larger drug 
consumption, we divided the yearly number of ampoules or PFS by the yearly number of 
anaesthetics in each centre. The latter was extracted from the French Medical Information 
System (programme de médicalisation des systèmes d’information [PMSI]). The PMSI is a 
national database in which activity data from French hospitals (both public and private) are 
prospectively collected, including the number of recorded anaesthetics. Hence, we expressed 
the use of vasopressors as a number of ampoule / PFS per 100 anaesthetics (abv: /100A). We 
first analysed the annual frequency of vasopressors use across all hospitals, and then we 
analysed data individually for each hospital depending on their category (CHU/HIA). We 
used descriptive statistics throughout.  
 
 
 
  
Results 
 
Participating centres  
Of the 39 CHUs and HIAs, 32 (82%) participated and completed the questionnaire (72% of 
CHU / 28% of HIA). We excluded four hospitals because data contained intensive care unit 
data (n=3) or because of incomplete answers (n=1), leading to an analysis set of 28 (72%) 
centres (21 CHU/ 7 HIA).  
Raw data on vasopressor consumption and anaesthetics (general, neuraxial or troncular) are 
summarised in Table 1.  
 
Overall data  
The four-year evolution of the number of delivered vasopressors per 100A is shown in Figure 
1. Before the marketing authorisation of diluted phenylephrine (<2011), concentrated 
phenylephrine ampoules were registered in 68% of hospitals (14 CHU/5 HIA) although 
consumption was limited (average of 5.6 ampoules/100A). Diluted phenylephrine became 
progressively available over the period and was finally registered in 100% of hospitals by the 
end of 2014. Seventeen centres (61%) had chosen the dilution 500µg/10ml, nine (32%) had 
registered the dilution 500µg/5ml, and two (7%) had both dilutions. The use of diluted 
phenylephrine increased exponentially during the observation period (1.0 ampoule/100A in 
2012, 12.3 in 2013 and 31.7 in 2014). Following the withdrawal of its marketing 
authorisation, consumption of concentrated phenylephrine became null. The use of ephedrine 
remained stable over time for both ampoule and PFS (on average 26.3 ampoules/100A and 
16.9PFS/100A). The consumption of norepinephrine slightly increased from 6.7 
ampoules/100A in 2011 to 8.2 in 2014.  
 
Individual data  
Trends in vasopressor consumption in CHUs and HIAs are shown in Figures 2a and 2b, 
respectively.  
Among CHUs, 67% had registered the concentrated form of phenylephrine in 2011 with an 
average of 2.9 ampoules/100A although large disparities were observed (range, 0 to 9.2 
ampoules/100A).  
Ninety per cent of CHUs had registered the diluted form phenylephrine from 2013, and 100% 
from 2014, the strength at 500µg/10ml being chosen in 81% of cases. In 2014, the average 
consumption of diluted phenylephrine was 15.7 ampoules/100A though with great variation 
between hospitals (range, 1.1 to 32.0 ampoules/100A).  
In 2011, ephedrine was available in PFS form in 12 centres (57%) and exclusively used in 
19% of cases. Eight centres (38%) had registered ephedrine both as PFS and ampoules (either 
diluted or concentrated).  
Between 2011 and 2014, one hospital switched from ephedrine PFS to ephedrine diluted 
ampoule. Two hospitals started using PFS, one in an exclusive manner (in replacement to 
concentrated ephedrine) and the other in association with diluted ephedrine ampoule. In the 
latter, the use of PFS was limited. 
Consumption of ephedrine in PFS slightly increased from 12.7PFS/100A in 2011 to 
14.6/100A in 2014. Hospitals that had been using ephedrine ampoules had a stable 
consumption over time (in average 29.7 ampoules/100A).  
The average consumption of norepinephrine was 7.8 ampoules/100A in 2011, then increased 
gradually over time (8.5 in 2012, 8.8 in 2013, and 9.7 ampoules/100A in 2014). Large 
disparities were observed in 2014 between hospitals (range, 0.8 to 22.2 ampoules/100A).  
In two centres (9.5%), the use of norepinephrine decreased. Moreover, these centres had a 
high consumption of ephedrine (around 60 ampoules or PFS/100A).  
Among HIAs, five (71%) registered concentrated phenylephrine in 2011. The average 
consumption was 13.8 ampoules/100A with large differences between hospitals (range, 0 to 
45.2 ampoules/100A).  
One hundred per cent of HIAs had registered diluted phenylephrine from 2013, the diluted 
form 500µg/5ml being chosen in 75% of cases. In 2014, the average consumption of diluted 
phenylephrine was 79.4 ampoules/100A, still with large disparities between centres (range, 
23.4 to 144.8 ampoules/100A).  
Seventy-one per cent of HIA (5 hospitals) had registered ephedrine PFS. Two centres (29%) 
had initially registered both ephedrine ampoules and PFS and progressively turned to 
increasingly exclusive consumption of ephedrine PFS.    
Ephedrine ampoules consumption decreased gradually between 2011 and 2014, from 20.0 
ampoules/100A in 2011 to 12.8 ampoules/100A in 2014. The same trend was observed for 
ephedrine as PFS, which= decreased from 33.7 PFS/100A in 2011 to 27.0 PFS/100A in 2014.  
The average consumption of norepinephrine was 3.5 ampoules/100A in 2011. A transitory 
reduction of norepinephrine use was observed in 2012 (2.3 ampoules/100A) since in 2013 the 
consumption increased (3.7 ampoules/100A in 2014).   
 
Discussion  
Our aim was to evaluate trends in medical practices following the release of a new form of 
phenylephrine more relevant to anaesthetic use, as a bolus of 50 to 100µg are often 
administered to patients.  
We found an overall increase in vasopressor consumption in the operation room, and an 
exponential use of diluted phenylephrine since its marketing authorisation.   
The former presentation of concentrated phenylephrine (5mg/1ml) had to be diluted to 
100µg/ml and had to be used within four hours. This might explain the relatively limited 
consumption of concentrated phenylephrine in 2011, which was registered in only 68% of 
centres. 
Following its commercialization, 100% of hospitals registered the diluted form of 
phenylephrine in the operating room. Interestingly, no decrease in use of other vasopressors 
was subsequently observed. Conversely, a trend toward more frequent use of norepinephrine 
was observed.  
The large variations in the use of vasopressors suggest heterogeneous practices among CHUs 
and HIAs. From 2011, HIAs used phenylephrine more frequently compared to CHUs, and this 
difference rose notably when diluted phenylephrine became available.  
In 2011, 39,878 ampoules of concentrated phenylephrine had been delivered to operating 
rooms which is not negligible compared to the 183,493 ampoules of diluted phenylephrine 
dispensed in 2014. However, due to inadequate presentation, only a small proportion of 
phenylephrine concentrated ampoules was administered to the patient. Hence, the amount of 
phenylephrine that was used in 2011 is probably overrated by the count of concentrated 
ampoule.  
When phenylephrine infusion is administered, several ampoules are given in the same 
intervention to maintain blood pressure. Our data provide an overall estimate of 
phenylephrine consumption but they do not accurately provide the exact amount of diluted 
phenylephrine needed per intervention.  
This observational study also demonstrates trends with respect to use of other vasopressors 
that can be used in the operating room. While ephedrine was initially released as concentrated 
ampoules (30mg/1mL), diluted ephedrine has been progressively available in the French 
market since the 2000s, firstly as PFS from 2003, then in ampoules from 2007. The main 
advantage of diluted ephedrine is its practicality compared to concentrated ephedrine as it 
does not necessitate any further dilution before administration. Hence, it prevents dilution 
errors.  
Surprisingly, 36% of centres still have concentrated ephedrine in addition to diluted ephedrine 
(ampoule or PFS) on their formulary. Overall, ephedrine consumption was relatively stable 
over time, the only changes being the registered form within centres. In CHUs, the use of PFS 
of ephedrine increased notably while in HIAs, increased consumption of diluted 
phenylephrine was associated with a decrease of ephedrine consumption (both ampoule and 
PFS). Ephedrine PFS can potentially improve safety of drug preparation and save nursing 
time 5. However, only 61% of hospitals reported its use. This is likely to be due to the 
additional cost of PFS compared to ampoules 6, 7. 
The use of norepinephrine increased between 2011 and 2014, with an average consumption of 
8.2 ampoules per 100 anaesthetics in 2014. The exponential increase in the use of 
phenylephrine was not associated with a decrease of other vasopressors. 
 
There is no universal definition for arterial hypotension. While hypotension may be defined as 
a blood pressure inferior to a threshold, some consider hypotension as a decrease of pressure 
from a baseline value1. Similarly, some define hypotension by mean arterial pressure whereas 
others define it by systolic arterial pressure. Lastly, some authors define intraoperative 
hypotension with a minimal duration of 5 or 10 min 1.  
Perioperative hypotension is an independent risk factor of cardiovascular and cerebrovascular 
morbidity. 8-10  
Anaesthesia-induced hypotension is partially limited by three pathways of regulation: the 
sympathetic nervous system, the renin angiotensin system (RAS), and the vasopressin system.  
Anaesthesiologists also have several means to prevent the onset of hypotension or to reduce 
its duration: the volemia optimization, the reduction of anaesthetic drug usage for an optimal 
level of sedation, and the injection of vasopressor drugs. Hypotension occurs more frequently 
in the operating room due to aging, and incidence of diseases like high blood pressure. 11, 12  
The high blood pressure-induced physiopathology (whether treated or not) is responsible for 
substantial haemodynamic changes secondary to anaesthesia induction. This is due to 
idiopathic deregulation of blood pressure, reduction of vessel compliance, or diastolic 
dysfunction of left ventricle. Treatments for high blood pressure can also modify 
haemodynamic stability. Diuretics generate hypovolemia while others treatments inhibit the 
autonomic adaptation system. 
When patients have coronary heart disease, the use of phenylephrine is relevant to treat 
hypotension. Phenylephrine has only alpha-adrenergic agonist activity, as opposed to 
ephedrine which has chronotropic and inotropic effects by beta-adrenergic receptor 
stimulation.  
When patients are under angiotensin-converting enzyme inhibitors (ACEIs) or antagonists of 
the receptor of angiotensin II (AIIRAs), hypotension is more frequent and severe. In this case, 
the first-line treatment is fluid resuscitation, then ephedrine. This vasopressor is more adapted 
than phenylephrine as a result of its alpha and beta-adrenergic effect.  
Refractory hypotensions are particularly frequent in patients with long-term ACEIs or 
AIIRAs treatment. A bolus of terlipressin (long-acting synthetic analog of vasopressin) 
generates a significant vasoconstriction, and notably has a quick and prolonged effect on 
blood pressure. 13 However, terlipressin leads to a reduction of cardiac output by reflex 
mechanism, and some authors have described a decrease of gut mucosal perfusion with 
terlipressin 14.  
Hypotension is also deeper with epidural anaesthesia, especially with thoracic position. In this 
situation, phenylephrine seems more effective than ephedrine. 15 
Due to potential interactions with anaesthesia drugs, ACEIs/AIIRA must be discontinued 
before surgery except in cases where patient have an important dyspnoea or a left ventricular 
failure 16. 
Recent data suggest that norepinephrine infusion is of use in high-risk patients to maintain 
blood pressure. By its adrenergic effects, norepinephrine increases systemic vascular 
resistance without adverse effects on oxygenation and perfusion in the intestinal tract. A trial 
17 is currently ongoing to analyse the incidence of postoperative organ failure and to compare 
the management of intraoperative arterial hypotension by norepinephrine versus ephedrine. 
 
The increase use of vasopressors may partially be explained by the release in 2013 of French 
guidelines for perioperative haemodynamic optimization. 18 
For high-risk patients, fluid management needs to be performed by titration, and has to be 
continued until stroke volume stops to increase (measured by oesophageal Doppler) or by 
monitoring dynamic parameters. This strategy based on cardiac output measurement reduces 
postoperative morbidity compared with the empirical strategy based on clinical parameters 
(blood pressure, heart rate).   
With these recommendations, the administration of vasopressors such as norepinephrine is 
earlier in case of intraoperative hypotension, if a fluid challenge is not efficient to increase 
cardiac output.  
These guidelines also insist on the treatment of maternal hypotension related to spinal 
anaesthesia for C-section. The management of such hypotension must be systematically 
associated a volume replacement with vasopressors. Phenylephrine is recommended as first 
agent to increase the venous return and with a limited placental transfer. 19, 20 
The association of ephedrine and phenylephrine has the advantage of avoiding maternal 
bradycardia. Some studies showed that norepinephrine could also avoid this reflex 
bradycardia. 21 
In November 2013, the European Medicines Agency decided to restrict the use of 
hydroxylethyl-starch solutions (HES) to the treatment of haemorrhagic shock when 
crystalloids are insufficient.  
This restriction on HES might also have contributed to the observed increase of vasopressors.  
 
This study has several limitations. First, we selected CHUs and HIAs and consequently we 
excluded private and secondary hospitals. However, one can assume that medical practices 
should be similar in those centres.  
Second, the duration of the observation period may be considered as too limited to accurately 
evaluate the changes in anaesthesiology practices. Since the time to registration for new drug 
on the formulary can significantly vary between hospitals, diluted phenylephrine has not been 
available simultaneously in the selected hospitals. Some hospitals were able to register diluted 
phenylephrine from 2013 whereas others used it from 2014. Although our study highlighted 
marked changes in practices since 2011, the situation on vasopressors use cannot be 
considered to have stabilised as of the end of 2014. Hence, an extended follow-up study could 
be beneficial in the next few years to confirm these trends seen in the current study.  
Our results may be considered as valid among French hospitals but cannot be generalised to 
other countries where the availability of vasopressor drugs may differ to those used in France. 
Lastly, we used the amount of ampoules/PFS dispensed by hospital pharmacies to operating 
rooms to estimate the changes on practices for the management of hypotension. This method 
is not optimal to accurately determine the real dose of drugs administered during surgeries. 
However, it can be considered as a good indicator in trends on anaesthesiology practices 22.   
 
Conclusion  
Since its marketing authorisation in 2012, diluted phenylephrine has been registered in 100% 
of French teaching and military hospitals and its use increased exponentially in the operating 
room while the consumption of other vasopressors remained stable. The overall increase of 
vasopressors use in French hospitals may be explained by changes in medical practices 
secondary to clearer evidence that the optimization of blood pressure and volume status in per 
operative period reduces post-operative morbidity.   
In most cases, intraoperative hypotension is treated by fluid administration and vasopressors. 
In some specific situations, transfusion or positive inotropic drug (like dobutamine) could be 
useful. 
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Figure 1 
National trends in vasopressor use per 100 anaesthetics during the period 2011-2014 
Evolution	  nationale	  des	  consommations	  en	  vasopresseurs	  pour	  100	  anesthésies	  sur	  la	  période	  2011-­‐
2014.	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Figure 2  
Trends in vasopressor use per 100 anaesthetics in CHU (a) and HIA (b) 
Evolution	  des	  consommations	  en	  vasopresseurs	  pour	  100	  anesthésies	  dans	  les	  CHU	  (a)	  et	  dans	  les	  
HIA	  (b)	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Table 1 
Yearly consumption of vasopressor and yearly numbers of anaesthetic for the 28-responding hospitals.  
Consommation annuelle de vasopresseurs et nombre annuel d’anesthésie dans les 28 hôpitaux répondeurs.  
 
YEAR 2011 2012 2013 2014 
Ephedrine ampoules (n) 235,250 248,430 252,183 244,756 
Ephedrine PFS (n) 134,941 137,946 144,139 160,352 
Concentrated phenylephrine ampoules (n) 39,878 45,610 22,716 24 
Diluted phenylephrine ampoules (n) 0 7,760 83,151 183,493 
Norepinephrine ampoules (n) 77,974 90,717 91,764 101,476 
Anaesthetics (n) 956,891 976,023 990,140 1,009,571 
 
PFS : prefilled syringe 
	  
Table 2: Four-year number of units of vasopressors per 100 anaesthetics.  
Consommation en vasopresseur pour 100 anesthésies sur les 4 années 2011-2014 
 
 
 
 
 
 
 
PFS: prefilled syringe 
In bold type: mean ± standard deviation; in italic type: median; in parentheses: minimum – maximum. 
 
 
	  
!
!
2011! !! 2012!
!
2013!
!
2014!
Ephedrine!ampoules!(n/100A)! 26.8%±%25.0% 18.9% (0%(71.9)%
!
27.2%±%24.6% 23.4% (0%–%63.6)%
!
26.1%±%25.1% 24.3% (0%–%64.8)%
!
25.1%±%25.7% 17.8% (0%–%67.0)%
Ephedrine!PFS!(n/100A)! 18.0%±%25.0% 4.4% (0%–%102.4)%
!
15.5%±%18.9% 6.8% (0%–%64.1)%
!
16.2%±%18.1% 10.9% (0%–%63.7)%
!
17.7%±%19.0% 16.7% (0%(72.5)%
Concentrated!phenylephrine!ampoules!(n/100A)! 5.6%±%9.3% 2.4% (0%–%45.2)%
!
5.4%±%6.9% 3.4% (0%–%27.0)%
!
2.8%±%2.9% 2.5% (0%–%9.2)%
!
0% 0% (%
Diluted!phenylephrine!ampoules!(n/100A)! 0% 0% (%
!
1.0%±%5.1% 0% (0%–%26.8)%
!
12.3%±%15.9% 5.5% (0%–%67.7)%
!
31.7%±%35.3% 18.9% (1.1%–%143.8)%
Norepinephrine!ampoules!(n/100A)! 6.7%±%5.0% 5.8% (1.3%–%21.7)%
!
7.0%±%5.4% 5.9% (1.3%–%23.0)%
!
7.3%±%5.5% 5.9% (0.9%–%21.6)%
!
8.2%±%5.4% 6.2% (0.8%–%22.2)%
